IL-40 levels in treatment-naïve and methotrexate-treated rheumatoid arthritis patients
Turkish Journal of Medical Sciences · 20.06.2025 · 55 (3) · 658-665
DOI: 10.55730/1300-0144.6013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 20.06.2025. Verfasst von Hamdi Oğuzman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Turkiye. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by persistent inflammation and progressive damage to the joints. In this study, it was aimed to explore the role of interleukin (IL)-40, a newly discovered cytokine, in the pathogenesis of RA. We also aimed to investigate the relationship between IL-40 and other cytokines such as IL-4, transforming growth factor (TGF)-β1 and tumor necrosis factor (TNF)-α. Materials and methods: This single-center, cross-sectional study included 87 participants divided into three groups: healthy controls (n = 29), newly diagnosed RA patients (n = 29), and RA patients with remission under methotrexate (MTX) monotherapy (n = 29). Serum samples were collected and analyzed for IL-40, IL-4, TGF-β1 and TNF-α levels using ELISA. Disease activity score, presence of autoantibodies and other relevant clinical data were obtained from hospital electronic records.
Results
Elevated IL-40 levels were found in the newly diagnosed RA patients and in those treated with MTX compared to the control group (p < 0.001). Logistic regression analysis confirmed IL-40 as an independent predictor in the newly diagnosed (OR = 1.023, 95% CI: 1.010–1.035, p = 0.002) and RA MTX-treated patients (OR = 1.023, 95% CI: 1.011–1.036, p < 0.001). IL-40 levels remained unchanged in the newly diagnosed RA group compared to RA patients in the MTX-treated group. In the dual-seropositive patients, TGF-β1 was lower in the MTX-treated RA patients compared to the naive patients (p = 0.013) and in the dual-seronegative patients, TNF-α was decreased in the MTX-treated RA patients in comparison to naive patients (p = 0.043).
Conclusion
This study demonstrates that IL-40 levels are elevated in RA patients and highlights its potential role in RA. The fact that IL-40 levels did not change despite the antiinflammatory effects of MTX suggests that IL-40 is involved in immunological pathways that are less responsive to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Turkiye.
- Department of Rheumatology-Internal Medicine, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Turkiye.
ORCID-Profile: Hamdi Oğuzman, Mete Pekdiker
Zitieren
APA
Oğuzman, H., & Pekdiker, M. (2025). IL-40 levels in treatment-naïve and methotrexate-treated rheumatoid arthritis patients. Turkish Journal of Medical Sciences, 55(3), 658-665. https://doi.org/10.55730/1300-0144.6013
Vancouver
Oğuzman H, Pekdiker M. IL-40 levels in treatment-naïve and methotrexate-treated rheumatoid arthritis patients. Turkish Journal of Medical Sciences. 2025;55(3):658-665. doi:10.55730/1300-0144.6013
BibTeX
@article{Ouzman2025,
author = {Oğuzman, Hamdi and Pekdiker, Mete},
title = {IL-40 levels in treatment-naïve and methotrexate-treated rheumatoid arthritis patients},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {3},
pages = {658--665},
doi = {10.55730/1300-0144.6013}
}
EUVIMED